Characteristics of patients in the study
| Characteristic | COPD n (%) | Non-COPD n (%) |
|---|---|---|
| Sex | ||
| Male | 21 053 (61.9) | 178 611 (67.1) |
| Female | 12 908 (37.9) | 86 504 (32.5) |
| Missing | 80 (0.2) | 956 (0.36) |
| Age (years) | ||
| <60 | 7627 (22.6) | 90 557 (34.1) |
| 60–70 | 8830 (26.0) | 62 947 (23.7) |
| 71–80 | 10 622 (31.3) | 61 549 (23.2) |
| >80 | 6786 (20.0) | 50 126 (18.9) |
| Missing | 0 | 0 |
| Smoking status | ||
| Current | 14 666 (43.2) | 90 026 (34.0) |
| Ex | 19 244 (56.8) | 87 612 (33.0) |
| Never | 0 | 87 541 (33.0) |
| Missing | 0 | 0 |
| Previous Angina | ||
| Yes | 7426 (21.8) | 41 417 (15.6) |
| No | 25 936 (76.2) | 223 089 (83.9) |
| Missing | 679 (2.0) | 1565 (0.6) |
| Previous PCI | ||
| Yes | 908 (2.7) | 6622 (2.5) |
| No | 32 082 (94.3) | 255 449 (96.0) |
| Missing | 1051 (3.1) | 3916 (1.5) |
| Previous CABG | ||
| Yes | 786 (2.3) | 5704 (2.1) |
| No | 32 227 (94.7) | 256 574 (96.4) |
| Missing | 1028 (3.0) | 3793 (1.4) |
| Diabetes | ||
| Yes—diet controlled | 1193 (3.5) | 8322 (3.1) |
| Yes—oral | 2902 (8.5) | 21 418 (8.1) |
| Yes—insulin | 1241 (3.7) | 8986 (3.4) |
| Yes—insulin and oral | 176 (0.5) | 1178 (0.4) |
| No | 28 030 (82.3) | 223 040 (83.8) |
| Missing | 499 (1.5) | 3127 (1.2) |
| Treated for hypertension | ||
| Yes | 15 304 (45.0) | 117 886 (44.3) |
| No | 18 151 (53.3) | 146 459 (55.1) |
| Missing | 586 (1.7) | 1726 (0.7) |
| Treated for hyperlipidaemia | ||
| Yes | 9091 (26.7) | 73 641 (27.7) |
| No | 23 399 (68.7) | 185 043 (69.6) |
| Missing | 1551 (4.6) | 7387 (2.8) |
| Peripheral vascular disease | ||
| Yes | 1962 (5.8) | 9061 (3.4) |
| No | 30 872 (90.7) | 253 720 (95.4) |
| Missing | 1207 (3.6) | 3290 (1.2) |
| Previous cerebrovascular disease | ||
| Yes | 2823 (8.3) | 16 829 (6.3) |
| No | 30 354 (89.2) | 247 418 (93.0) |
| Missing | 864 (2.5) | 1824 (0.7) |
| Heart failure | ||
| Yes | 2037 (6.0) | 7426 (2.8) |
| No | 31 080 (91.3) | 256 677 (96.5) |
| Missing | 924 (2.71) | 1968 (0.7) |
| Renal failure | ||
| Yes | 1681 (4.9) | 8428 (3.2) |
| No | 31 452 (92.4) | 255 732 (96.1) |
| Missing | 908 (2.7) | 1911 (0.7) |
| β blocker on arrival | ||
| Yes | 3016 (8.9) | 44 585 (16.8) |
| No | 23 544 (69.1) | 162 876 (61.2) |
| Missing | 7481 (22.0) | 58 610 (22.0) |
| ACEi/ARB on arrival | ||
| Yes | 8228 (24.2) | 57 288 (21.53) |
| No | 18 331 (53.9) | 150 036 (56.4) |
| Missing | 7482 (22.0) | 58 747 (22.1) |
| Statin on arrival | ||
| Yes | 9446 (27.8) | 65 062 (24.5) |
| No | 17 409 (51.1) | 144 498 (54.3) |
| Missing | 7186 (21.1) | 56 511 (21.2) |
| Thienopyridine on arrival | ||
| Yes | 2948 (8.7) | 23 240 (8.7) |
| No | 22 729 (66.8) | 176 548 (66.4) |
| Missing | 8364 (24.6) | 66 283 (24.9) |
| Death in hospital | 1561 (4.6) | 8574 (3.2) |
| Death at 180 days (survivors to discharge) | 4166 (12.8) | 19 693 (7.7) |
ACEi, ACE inhibitor; ARB, angiotensin receptor blocker; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; PCI, percutaneous coronary intervention.